Egetis Therapeutics AB (publ) (EGTX) — Capital Reinvestment Ratio

Latest as of June 2011: 1.30x

Egetis Therapeutics AB (publ) (EGTX) has a Capital Reinvestment Ratio of 1.30x as of June 2011, meaning it reinvests 1% of its operating cash flow (Skr1.84 Million) in capital expenditures (Skr2.38 Million). See EGTX free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

1.30x

Capex / Operating Cash Flow

Operating Cash Flow

Skr1.84 Million

SEK

Capital Expenditures

Skr2.38 Million

SEK

Data as of

Jun 2011

Most recent filing

Annual Capital Reinvestment Ratio for Egetis Therapeutics AB (publ) (None–None)

Year-by-year Capital Reinvestment Ratio for Egetis Therapeutics AB (publ) from None to None. For live market cap and broader valuation context, see Egetis Therapeutics AB (publ) market capitalisation.

Year	Reinvestment Ratio	Operating CF (SEK)	Capital Expenditures	YoY Change

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow